Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis
- VernacularTitle:瑞美替罗（Resmetirom）治疗代谢相关脂肪性肝炎的临床试验进展
- Author:
Aifang LIU
1
;
Lei LUO
1
;
Wenlong YANG
1
Author Information
- Publication Type:Review
- Keywords: Metabolic Dysfunction-Associated Steatohepatitis; Resmetirom; Clinical Trial
- From: Journal of Clinical Hepatology 2025;41(1):145-150
- CountryChina
- Language:Chinese
- Abstract: Metabolic dysfunction-associated steatotic liver disease is the largest liver disease around the world and is a serious public health hazard， but there has always been a lack of drugs approved for treatment. On March 14， 2024， Resmetirom became the first drug approved by the US Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis （MASH）. This article summarizes the mechanism of action of Resmetirom in the treatment of MASH， related clinical trial designs， and some research results and analyzes shortcomings and future prospects. Current data have shown that Resmetirom is effective in improving steatohepatitis and liver fibrosis， but there is still a large gap between Resmetirom and the ideal drug for the treatment of MASH， and it is expected to develop more effective drugs for MASH.
